Who
Timothy C. Dec
Senior Vice-President & CFO
Company insider
Files Form 4 as: Senior Vice-President & CFO, Supernus Pharmaceuticals; Chief Financial Officer, Opgen; Chief Financial Officer, Tss; SVP Ch. Acct. Officer & Treas., Broadwing.
In numbers
- Trades disclosed
- 148
- Buys
- 3
- Sells
- 2
- Bought
- $50K
- Sold
- $745K
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 20 Mar 2006
- Last trade
- 12 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —1,250 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $28K604 at $46.57 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,250 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,250 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —1,250 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $28K604 at $46.57 | filing |
| 29 Jul 2026filed 31 Jul 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,250 at $0.00 | filing |
| 29 Jul 2026filed 31 Jul 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,250 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $78K1,433 at $54.73 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $79K1,450 at $54.73 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $78K1,433 at $54.73 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $79K1,450 at $54.73 | filing |
News
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026SUPN · manilatimes.net · 19 Oct 2026Supernus Pharmaceuticals (NASDAQ:SUPN) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Critical SurveySUPN · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Timothy C. Dec; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.